Rapamycin to the rescue?
Cancer cases and deaths among men are projected to skyrocket by 2050, according to a new study, especially for those aged 65 and older. The research, published in the journal Cancer, showed the current sharp disparity in cancer mortality and cases among men is likely to increase without interventions.
Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35458
https://thehill.com/policy/healthcare/4824044-men-cancer-deaths-mortality-rate-risk-factors/
Related Reading:
Rapamycin is generally considered anti-cancer, and is used (and is FDA-approved) for cancer treatments (certain cancers, more so with the everolimus version of rapamycin (also called a rapalog),
see: Rapamycin - for Cancer Prevention
and: Everolimus (Afinitor) | Cancer information | Cancer Research UK
and: Rapamycin and cancer. What I’ve learned
and: Everolimus (Rapalog): Teen 'cured' of brain cancer in world first as docs 'watched tumour disappear'
but rapamycin does seem to slightly increase the susceptibility to sunburn and thereby could potentially increase risk of skin cancer, so always wear sun screen when using rapamycin: Rapamycin - skin cancer
Strangely, rapamycin also seems to be anti-skin cancer: Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression - PMC